Tau-negative amnestic dementia masquerading as Alzheimer disease dementia

Hugo Botha, William G. Mantyh, Jonathan Graff-Radford, Mary Margaret Machulda, Scott A. Przybelski, Heather J. Wiste, Matthew L. Senjem, Joseph E Parisi, Ronald Carl Petersen, Melissa E Murray, Bradley F Boeve, Val Lowe, David S Knopman, Clifford R Jr. Jack, David T Jones

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective To describe the phenomenon of tau-negative amnestic dementia mimicking Alzheimer disease (AD) clinically and radiologically and to highlight the importance of biomarkers in AD research. Methods Eight participants with amnestic mild cognitive impairment or AD dementia were evaluated by a behavioral neurologist and had a standardized neuropsychological battery performed. All participants completed structural (MRI) and molecular (amyloid and tau PET) imaging. AD-signature thickness and adjusted hippocampal volume served as structural biomarkers, while standardized uptake value ratios (SUVRs) from validated regions of interest for amyloid and tau PET were used to determine molecular biomarker status. Results All participants were thought to have AD as the primary driver of their symptoms before any PET imaging. All participants had hippocampal atrophy, and 2 participants fell below the AD-signature thickness cutoff for elderly controls (2.57), with a further 3 falling below the more stringent cutoff based on young controls (2.67). Four participants were amyloid positive (SUVR >1.42), and all were tau negative (SUVR <1.33). Conclusions The participants presented here were clinically impaired, with structural imaging evidence of neurodegeneration, in the absence of any significant tau accumulation. Therefore, AD is unlikely as a cause of their clinical presentation and neurodegenerative imaging findings. Several implications are discussed, including the need to establish amyloid and tau positivity in N+ participants before enrolling them in trials of disease-modifying therapy agents for AD.

Original languageEnglish (US)
Pages (from-to)e940-e946
JournalNeurology
Volume90
Issue number11
DOIs
StatePublished - Mar 13 2018

Fingerprint

Dementia
Alzheimer Disease
Amyloid
Biomarkers
Accidental Falls
Atrophy
Research

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Tau-negative amnestic dementia masquerading as Alzheimer disease dementia. / Botha, Hugo; Mantyh, William G.; Graff-Radford, Jonathan; Machulda, Mary Margaret; Przybelski, Scott A.; Wiste, Heather J.; Senjem, Matthew L.; Parisi, Joseph E; Petersen, Ronald Carl; Murray, Melissa E; Boeve, Bradley F; Lowe, Val; Knopman, David S; Jack, Clifford R Jr.; Jones, David T.

In: Neurology, Vol. 90, No. 11, 13.03.2018, p. e940-e946.

Research output: Contribution to journalArticle

@article{187b220e00ad40a8964ba08a427d8bda,
title = "Tau-negative amnestic dementia masquerading as Alzheimer disease dementia",
abstract = "Objective To describe the phenomenon of tau-negative amnestic dementia mimicking Alzheimer disease (AD) clinically and radiologically and to highlight the importance of biomarkers in AD research. Methods Eight participants with amnestic mild cognitive impairment or AD dementia were evaluated by a behavioral neurologist and had a standardized neuropsychological battery performed. All participants completed structural (MRI) and molecular (amyloid and tau PET) imaging. AD-signature thickness and adjusted hippocampal volume served as structural biomarkers, while standardized uptake value ratios (SUVRs) from validated regions of interest for amyloid and tau PET were used to determine molecular biomarker status. Results All participants were thought to have AD as the primary driver of their symptoms before any PET imaging. All participants had hippocampal atrophy, and 2 participants fell below the AD-signature thickness cutoff for elderly controls (2.57), with a further 3 falling below the more stringent cutoff based on young controls (2.67). Four participants were amyloid positive (SUVR >1.42), and all were tau negative (SUVR <1.33). Conclusions The participants presented here were clinically impaired, with structural imaging evidence of neurodegeneration, in the absence of any significant tau accumulation. Therefore, AD is unlikely as a cause of their clinical presentation and neurodegenerative imaging findings. Several implications are discussed, including the need to establish amyloid and tau positivity in N+ participants before enrolling them in trials of disease-modifying therapy agents for AD.",
author = "Hugo Botha and Mantyh, {William G.} and Jonathan Graff-Radford and Machulda, {Mary Margaret} and Przybelski, {Scott A.} and Wiste, {Heather J.} and Senjem, {Matthew L.} and Parisi, {Joseph E} and Petersen, {Ronald Carl} and Murray, {Melissa E} and Boeve, {Bradley F} and Val Lowe and Knopman, {David S} and Jack, {Clifford R Jr.} and Jones, {David T}",
year = "2018",
month = "3",
day = "13",
doi = "10.1212/WNL.0000000000005124",
language = "English (US)",
volume = "90",
pages = "e940--e946",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Tau-negative amnestic dementia masquerading as Alzheimer disease dementia

AU - Botha, Hugo

AU - Mantyh, William G.

AU - Graff-Radford, Jonathan

AU - Machulda, Mary Margaret

AU - Przybelski, Scott A.

AU - Wiste, Heather J.

AU - Senjem, Matthew L.

AU - Parisi, Joseph E

AU - Petersen, Ronald Carl

AU - Murray, Melissa E

AU - Boeve, Bradley F

AU - Lowe, Val

AU - Knopman, David S

AU - Jack, Clifford R Jr.

AU - Jones, David T

PY - 2018/3/13

Y1 - 2018/3/13

N2 - Objective To describe the phenomenon of tau-negative amnestic dementia mimicking Alzheimer disease (AD) clinically and radiologically and to highlight the importance of biomarkers in AD research. Methods Eight participants with amnestic mild cognitive impairment or AD dementia were evaluated by a behavioral neurologist and had a standardized neuropsychological battery performed. All participants completed structural (MRI) and molecular (amyloid and tau PET) imaging. AD-signature thickness and adjusted hippocampal volume served as structural biomarkers, while standardized uptake value ratios (SUVRs) from validated regions of interest for amyloid and tau PET were used to determine molecular biomarker status. Results All participants were thought to have AD as the primary driver of their symptoms before any PET imaging. All participants had hippocampal atrophy, and 2 participants fell below the AD-signature thickness cutoff for elderly controls (2.57), with a further 3 falling below the more stringent cutoff based on young controls (2.67). Four participants were amyloid positive (SUVR >1.42), and all were tau negative (SUVR <1.33). Conclusions The participants presented here were clinically impaired, with structural imaging evidence of neurodegeneration, in the absence of any significant tau accumulation. Therefore, AD is unlikely as a cause of their clinical presentation and neurodegenerative imaging findings. Several implications are discussed, including the need to establish amyloid and tau positivity in N+ participants before enrolling them in trials of disease-modifying therapy agents for AD.

AB - Objective To describe the phenomenon of tau-negative amnestic dementia mimicking Alzheimer disease (AD) clinically and radiologically and to highlight the importance of biomarkers in AD research. Methods Eight participants with amnestic mild cognitive impairment or AD dementia were evaluated by a behavioral neurologist and had a standardized neuropsychological battery performed. All participants completed structural (MRI) and molecular (amyloid and tau PET) imaging. AD-signature thickness and adjusted hippocampal volume served as structural biomarkers, while standardized uptake value ratios (SUVRs) from validated regions of interest for amyloid and tau PET were used to determine molecular biomarker status. Results All participants were thought to have AD as the primary driver of their symptoms before any PET imaging. All participants had hippocampal atrophy, and 2 participants fell below the AD-signature thickness cutoff for elderly controls (2.57), with a further 3 falling below the more stringent cutoff based on young controls (2.67). Four participants were amyloid positive (SUVR >1.42), and all were tau negative (SUVR <1.33). Conclusions The participants presented here were clinically impaired, with structural imaging evidence of neurodegeneration, in the absence of any significant tau accumulation. Therefore, AD is unlikely as a cause of their clinical presentation and neurodegenerative imaging findings. Several implications are discussed, including the need to establish amyloid and tau positivity in N+ participants before enrolling them in trials of disease-modifying therapy agents for AD.

UR - http://www.scopus.com/inward/record.url?scp=85050275469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050275469&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000005124

DO - 10.1212/WNL.0000000000005124

M3 - Article

C2 - 29438037

AN - SCOPUS:85050275469

VL - 90

SP - e940-e946

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 11

ER -